Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan. 25 deadline, Bloomberg reported Monday. A Starboard-backed director—or two—would have given the investor more leverage as it attempts to influence Pfizer’s turnaround strategy.
read moreThe company’s board of directors unanimously rejected partner Biogen’s $469 million buyout proposal, finding that it “significantly undervalues” the company and is not in the best interest of shareholders. More: No deal: Sage rejects Biogen's buyout offer, scouts for strategic
read more
Study highlights VE303’s potential in reducing recurrent CDI More: Vedanta Biosciences reveals Phase 2 VE303 results Source: News
read more
Comparison shows improved survival rates for pancreatic cancer treatment More: Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX Source: News
read moreModerna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare professionals and problems with the disclosure of transfers of value, respectively.
read moreNot long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch with a new commercial leader. More: Gearing
read more© 1994 - 2026 B.M. Pharmaceuticals